concept

Adavosertib

Also known as: AZD1775

Facts (6)

Sources

Perspectives on cancer therapy—synthetic lethal precision medicine ... nature.com Nature Apr 16, 2025 6 facts

referenceA phase I study by Leijen et al. (2016) evaluated the WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.

referenceA 2016 phase I study published in the Journal of Clinical Oncology by Leijen et al. evaluated the Wee1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.

referenceA phase I study by Do et al. (2015) evaluated the Wee1 kinase inhibitor AZD1775 (MK-1775) as a single agent in patients with refractory solid tumors.

referenceA dose escalation trial by Cuneo et al. (2019) evaluated the Wee1 inhibitor adavosertib (AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer.

referenceA 2019 dose escalation trial published in the Journal of Clinical Oncology by Cuneo et al. evaluated the Wee1 inhibitor adavosertib (AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer.

referenceA 2015 phase I study published in the Journal of Clinical Oncology by Do et al. evaluated the Wee1 kinase inhibitor AZD1775 (MK-1775) as a single agent in patients with refractory solid tumors.